NHS Formulary Inclusion for Medical Cannabis: What It Would Take

The Current State of NHS Cannabis Prescribing

• NHS prescribing of cannabis-based medicines remains extremely limited in practice
• NICE guidelines support use of nabilone for chemotherapy-induced nausea in specific circumstances
• Epidyolex is available on the NHS for specific rare childhood epilepsy syndromes
• The vast majority of medical cannabis in the UK is accessed through private prescribing

The gap between the theoretical availability of medical cannabis on the NHS and the practical reality of NHS prescribing is one of the defining characteristics of the UK market. Since the 2018 rescheduling, NHS prescribing has not materialised at scale. The structural reasons for this — cost, evidence standards, clinical conservatism, and NHS commissioning processes — are well understood by the industry but represent a sustained challenge to equitable patient access.

NICE Evaluation and Technology Appraisal Requirements

• NICE technology appraisals require randomised controlled trial evidence of clinical and cost-effectiveness
• The absence of large-scale RCTs for most medical cannabis indications is a significant barrier
• Single technology appraisals can take 18 to 24 months from initiation to final guidance
• Positive NICE guidance is a necessary but not always sufficient condition for NHS commissioning

NICE is the primary gateway for NHS formulary inclusion of new medicines. The Technology Appraisal process requires high-quality clinical evidence — ideally from randomised controlled trials — combined with health economic modelling demonstrating cost-effectiveness relative to existing treatments. For medical cannabis, the evidence base for most indications currently falls short of what NICE requires for a positive appraisal. Addressing this gap requires investment in clinical trials — which in turn requires commercial actors who believe the NHS market is worth the investment.

Building the Evidence Base for NHS Inclusion

• Prospective clinical registries and observational studies are valuable stepping stones to RCT evidence
• Academic-industry partnerships can reduce the cost of clinical trial infrastructure
• Real-world evidence from existing private prescribing can be used to design and power future RCTs
• Patient advocacy organisations can support trial recruitment and raise the profile of cannabis research

The evidence gap that currently prevents NHS formulary inclusion of medical cannabis is not insurmountable, but closing it requires sustained, coordinated investment. Real-world evidence from the growing private prescribing sector, combined with well-designed observational studies and eventually randomised controlled trials, can build the evidence base that NICE requires. This is a multi-year endeavour that requires collaboration between industry, academic institutions, NHS clinical networks, and patient organisations.

The Commercial Case for Pursuing NHS Inclusion

• NHS formulary inclusion would dramatically expand the patient population with access to medical cannabis
• NHS pricing and reimbursement dynamics differ significantly from the private prescribing market
• Volume gains from NHS inclusion could offset lower unit margins compared to private prescribing
• NHS credibility would strengthen the international reputation of UK-approved cannabis products

The commercial case for investing in the evidence base needed for NHS formulary inclusion is compelling but complex. The volume of patients who could access medical cannabis through NHS prescribing far exceeds the current private market, but NHS reimbursement pricing would be significantly lower. Companies whose business models can accommodate lower unit margins at much higher volumes — and who can tolerate the multi-year investment horizon — stand to benefit enormously from being positioned as established NHS suppliers when formulary inclusion eventually occurs.